Jean-Mathieu Beauregard
Chercheur universitaire clinicien
Axe Oncologie
Publications
View all-
article Mansouri Z, Salimi Y, Akhavanallaf A, Shiri I, Teixeira EPA, Hou X, Beauregard JM, Rahmim A, Zaidi H
Deep transformer-based personalized dosimetry from SPECT/CT images: a hybrid approach for [177Lu]Lu-DOTATATE radiopharmaceutical therapy
Eur J Nucl Med Mol Imaging 51 (6), 2024.
-
article Hansen AR, Probst S, Beauregard JM, Viglianti BL, Michalski JM, Tagawa ST, Sartor O, Tutrone RF, Oz OK, Courtney KD, Delpassand ES, Nordquist LT, Osman MM, Chi KN, Sparks R, George N, Hawley SM, Wu W, Jensen JD, Fleshner NE
Initial clinical experience with [177Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer: dosimetry, safety, and efficacy from the lead-in cohor…
Front Oncol 14 2024.
-
article Schürrle SB, Eberlein U, Ansquer C, Beauregard JM, Durand-Gasselin L, Grønbæk H, Haug A, Hicks RJ, Lenzo NP, Navalkissoor S, Nicolas GP, Pais B, Volteau M, Wild D, McEwan A, Lassmann M
Dosimetry and pharmacokinetics of [177Lu]Lu-satoreotide tetraxetan in patients with progressive neuroendocrine tumours
Eur J Nucl Med Mol Imaging 51 (8), 2024.
Projects
- Towards Personalized Dosimetry-Based Radioligand Therapy of Prostate Cancer as a New Standard of Practice, from 2022-04-01 to 2027-03-31
- Équipement de laboratoire radiopharmaceutique pour la théranostique et l'imagerie moléculaire innovantes, from 2022-07-01 to 2025-06-30
- Screening of gastroenteropancreatic neuroendocrine tumors from patients for temozolomide-induced upregulation of SSTR2: Towards improved PRRT, from 2023-04-01 to 2025-12-31
- Tirer profit des données de soins en contexte réel pour une introduction responsable, efficiente et équitable des innovations thérapeutiques en oncologie : la plateforme MEDOnco-VieRéelle, from 2024-09-01 to 2027-08-31
- Enhancing the PARADIM platform to bridge the gap between data and AI in medical imaging, from 2024-09-01 to 2027-08-31
- Les agents theranostiques: anticorps monoclonaux conjugués au médicament et marqués aux radioisotopes 89Zr/225Ac contre le récepteur du facteur de croissance épidermique des cancers colorectal- essai clinique prometteur, from 2024-09-01 to 2027-10-31
- 161Tb/225Ac-labeled anti-Nectin-4 radioimmunoconjugates with/without immune checkpoint inhibitors against NSCLC, from 2025-04-01 to 2030-03-30
- Development of GMP-grade anti-Nectin-4 radioimmunoconjugates, and clinical trial enabling studies for phase 1 trial against Nectin-4 positive NSCLC and TNBC, from 2025-03-11 to 2028-02-29
- Optimiser les soins des patients atteints du cancer de la prostate résistant à la castration en utilisant une stratégie de triple traceur en imagerie moléculaire et en radiothérapieléculaire et en radiothérapie ciblée, from 2018-04-01 to 2023-06-30
- Théranostique personnalisée du cancer de la prostate, from 2022-07-01 to 2024-06-30
- Potentiation of PRRT by chemotherapy-mediated upregulation of somatostatin receptor 2 in NET cell lines-derived tumors in mice and in Lung NET patient-derived tumor explants, from 2022-04-01 to 2024-12-31